MINNEAPOLIS, July 05, 2022 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2022 after the close of trading on Tuesday, August 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
To access the call, please use the following link: Inspire’s Q2 2022 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
A simultaneous webcast of the call will be accessible via the Investor Relations page of the Inspire’s website at www.inspiresleep.com. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Following the call, a replay will be available on the Company’s Investor Relations website approximately two hours after the event and archived on the site for two weeks.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…